immunkemoterápiát

Immunkemoterápii, sometimes referred to as chemoimmunotherapy, is a type of cancer treatment that combines chemotherapy with immunotherapy. Chemotherapy involves the use of drugs to kill cancer cells, while immunotherapy harnesses the body's own immune system to fight cancer. In immunkemoterápii, these two approaches are used together, either concurrently or sequentially, with the goal of enhancing the effectiveness of each.

The rationale behind combining these treatments is that chemotherapy can sometimes make cancer cells more visible to the immune system, or it may reduce the number of suppressor cells that hinder the immune response. This can potentially allow immunotherapy agents, such as checkpoint inhibitors or adoptive cell therapies, to work more effectively. For example, chemotherapy might induce the release of tumor antigens, which can then be recognized by the immune system.

The specific drugs and treatment schedules used in immunkemoterápii vary greatly depending on the type and stage of cancer being treated, as well as the individual patient's overall health. This approach is being investigated and used in various cancers, including lung cancer, melanoma, and certain lymphomas. Clinical trials continue to explore optimal combinations and sequencing of chemotherapy and immunotherapy to maximize patient outcomes while managing potential side effects, which can include those associated with both chemotherapy and immunotherapy.